Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer

NCT00856037 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Small Cell Lung Carcinoma

Interventions

DRUG: Doxorubicin Hydrochloride
OTHER: Laboratory Biomarker Analysis
OTHER: Quality-of-Life Assessment
DRUG: Topotecan Hydrochloride

Sponsor

University of Nebraska

Collaborators

[object Object]